Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study.
Giuseppina NovoFrancesca MacaioneLydia GiannitrapaniMaria Giovanna MinissaleVito BonomoFrancesco IndovinaSalvatore PettaMaria Giovanna MinissaleGiuseppe MontaltoSalvatore NovoAntonio CraxiAnna LicataPublished in: Alimentary pharmacology & therapeutics (2018)
HCV-cirrhotics show a significant rate of subclinical cardiac and vascular abnormalities. At a time when their survival is less linked to progression of liver disease, due to viral eradication on DAAs, cardiovascular morbidity and mortality may take a significant role.